INESSS Recommendation to Deny Reimbursement for Multiple Myeloma Treatment is a Global Outlier [Yahoo! Finance]
Karyopharm Therapeutics Inc. (KPTI)
Last karyopharm therapeutics inc. earnings: 2/13 07:00 am
Check Earnings Report
US:NASDAQ Investor Relations:
investors.karyopharm.com/investor-relations
Company Research
Source: Yahoo! Finance
Christian Dubé, Minister of Health and Social Services in Quebec to deny listing X POVIO ® (selinexor) in combination with V ELCADE ® (bortezomib) and d examethasone (XVd) for the treatment of adult patients with multiple myeloma (MM) who have received at least one prior therapy. This decision was based on a narrow and flawed interpretation of the data, resulting in a negative recommendation by the Institut national d'excellence en santé et en services sociaux (INESSS), the drug reimbursement agency in Quebec FORUS stands by its submission that the clinical issues related to the therapeutic value of XPOVIO were identified and addressed in the submission to INESSS. This negative recommendation is entirely inconsistent with expert physician input and the identified needs of MM patients who have limited treatment options. For all MM patients, the course of their disease involves several periods of remission and relapse until resistance develops to available therapies. It is therefore c
Show less
Read more
Impact Snapshot
Event Time:
KPTI
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KPTI alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KPTI alerts
High impacting Karyopharm Therapeutics Inc. news events
Weekly update
A roundup of the hottest topics
KPTI
News
- Karyopharm to Report First Quarter 2024 Financial Results on May 8, 2024PR Newswire
- Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)PR Newswire
- Karyopharm Therapeutics: Spiraling Despite Upcoming Catalysts [Seeking Alpha]Seeking Alpha
- Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Karyopharm Announces Presentations in Endometrial Cancer and Myelofibrosis at the 2024 American Society of Clinical Oncology Annual MeetingPR Newswire
KPTI
Earnings
- 2/29/24 - Miss
KPTI
Sec Filings
- 4/23/24 - Form 4
- 4/19/24 - Form ARS
- 4/19/24 - Form DEFA14A
- KPTI's page on the SEC website